Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

1231P - Clinical characteristics and real-world treatment patterns in stage I-III resectable NSCLC: THASSOS-INTL study

Date

14 Sep 2024

Session

Poster session 04

Topics

Therapy;  Supportive and Palliative Care

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Kumar Prabhash

Citation

Annals of Oncology (2024) 35 (suppl_2): S775-S793. 10.1016/annonc/annonc1600

Authors

K. Prabhash1, R. Moor2, T. Goksel3, S.F. Nyaw4, A.K. Altwairgi5, F.J. Gonzalez Hernandez6, E. Mohamed7, P. Kantharaju8, F. Sadek9

Author affiliations

  • 1 Medical Onclogy Department, Tata Memorial Hospital, 400012 - Mumbai/IN
  • 2 Princess Alexandra Hospital, Mater Cancer Care Centre, 4101 - South Brisbane/AU
  • 3 Pulmonary Medicine, Ege University - Faculty of Medicine, 35100 - Izmir/TR
  • 4 Clinical Oncology, Tuen Mun Hospital, Tuen Mun/HK
  • 5 Oncology Department, KFMC - King Fahad Medical City, 11525 - Riyadh/SA
  • 6 International Medical Affairs, AstraZeneca Plc, 6340 - Baar/CH
  • 7 Medical Affairs, AstraZeneca Gulf FZ LLC, Dubai/AE
  • 8 Department Of Oncology, AstraZeneca India, 560045 - Bangalore/IN
  • 9 Clinical Pharmacy, Cairo University, 12613 - Giza/EG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1231P

Background

The THASSOS-INTL (NCT04808050) evaluated the treatment (Tx) patterns and associated outcomes in patients (pts) with early-stage NSCLC from 7 countries in Asia-Pacific, and Middle East and Africa.

Methods

This multi-national, retrospective study enrolled adult pts (≥18 yrs) with resectable clinical stage (CS) IA-IIIB NSCLC diagnosed from 2013 to 2017, and followed until death, last recorded clinical visit, or 31 Dec 2020 (data cutoff). We present descriptive data on clinico demographics and Tx patterns (surgery [Sx], neoadjuvant therapy [NT], adjuvant therapy [AT], and NT+AT) of the overall cohort.

Results

Of 755 pts enrolled (CS I: 231 [30.6%], CS II: 264 [35.0%], CS III: 258 [34.2%]), median age was 62 [range: 56–69] yrs, 69.3% (523/755) were male, 75.0% (492/656) were current/former smokers, and 92.2% (436/473) had ECOG ≤1. Majority had adenocarcinoma (60.8% [434/714]), T1a–T2b tumors (65.9% [496/753]), right-lung involvement (58.9% [439/745]), and N0 status (55.6% [419/753]). Of 24.2% (183/755) pts tested for EGFR, 28.4% (52/183) were positive while 23 of 44 pts tested (52.3%) had PD-L1 expression (≥1%: 16; unknown: 7). Overall, 82.9% (626/755) had Sx of whom 39.1% (245/626) had Sx alone; 21.1% received NT, 51.1% received AT, and 5.8% received NT+AT (Table). In total, 58 pts received targeted therapy (AT: 47; NT:11), and 24 pts received immunotherapy (AT: 22; NT: 2). Of 43.8% (331/755) with disease progression, 68.3% (226/331) received systemic therapy (ST) and 50.2% (166/331) received radiotherapy (RT). Table: 1231P

Tx Overall 755 IA 106 IB 125 IIA 135 IIB 129 IIIA 217 IIIB 41
Sx n, % 626, 82.9 101, 95.3 118, 94.4 119, 88.1 108, 83.7 168, 77.4 11, 26.8
Sx only n, % 245, 39.1 80, 79.2 68, 57.6 32, 26.9 32, 29.6 31, 18.5 2, 18.2
NT n, % 159, 21.1 8, 7.5 11, 8.8 21, 15.6 26, 20.2 71, 32.7 21, 51.2
ST n, % 103, 64.8 4, 50.0 10, 90.9 16, 76.2 20, 76.9 45, 63.4 8, 38.1
RT n, % 3, 1.9 3, 37.5 0 0 0 0 0
ST + RT n, % 53, 33.3 1, 12.5 1, 9.1 5, 23.8 6, 23.1 26, 36.6 13, 61.9
AT, n, % 386, 51.1 20, 18.9 47, 37.6 85, 63.0 74, 57.4 138, 63.6 21, 51.2
ST n, % 268, 69.4 15, 75.0 37, 78.7 77, 90.6 57, 77.0 69, 50.0 12, 57.1
RT n, % 23, 6.0 3, 15.0 5, 10.6 1, 1.2 5, 6.8 8, 5.8 1, 4.8
ST + RT n, % 95, 24.6 2, 10.0 5, 10.6 7, 8.2 12, 16.2 61, 44.2 8, 38.1
NT + AT n, % 44, 5.8 2, 1.9 1, 0.8 6, 4.4 5, 3.9 27, 12.4 3, 7.3

Conclusions

This real-world study shows that ⁓39% of pts underwent Sx only, mostly in CS I, and ⁓70% received NT/AT, mostly in CS II and CS III. Biomarker testing at diagnosis was low with <25% tested for EGFR and <10% for PD-L1. With recent readouts of new NT and AT targeted and immunotherapies, multidisciplinary team management may improve biomarker testing rates and the use of novel agents in NT and/or AT settings for eligible pts to improve survival.

Clinical trial identification

NCT04808050.

Editorial acknowledgement

The authors would also like to thank Dr. Debasri Mukherjee and Dr. Soma Das of Fortrea Scientific Pvt Ltd for medical writing support that was funded by AstraZeneca International in accordance with Good Publication Practices 2022 guidelines.

Legal entity responsible for the study

AstraZeneca International.

Funding

AstraZeneca International.

Disclosure

K. Prabhash: Financial Interests, Institutional, Research Grant: Janssen, Aurigene, Roche. R. Moor: Financial Interests, Institutional, Other, Travel and meeting support: MSD, BMS, AstraZeneca, Roche, Novartis. F.J. Gonzalez Hernandez, E. Mohamed, P. Kantharaju, F. Sadek: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.